Introduction

▼
Jobelyn
® (JB) is a dietary supplement that has won both local and international recognition as anti-anaemic, immune booster and energizer [ 1 ] . JB is one of the fastest selling herbal medicines in Nigeria with most pharmaceutical outlets being used as the distribution channels. It is available as a powdered preparation formulated into capsules and suspensions for the treatment of moderate to severe anaemia (as in sickle cell patients), cancer and HIV/AIDS [ 2 ] . It is widely used to combat stress and to restore the much needed energy during the periods of recovery from debilitating diseases or sudden weight loss [ 1 , 2 ] . It is also claimed to be helpful in arthritis and neurological disorders [ 1 -3 ] . Additionally, JB is also known to strengthen the immune system, thereby enhances body's defensive mechanisms in response to stress or pathogenic invasions anti-depressant-like property in the mouse forced swimming test (FST), tail suspension test (TST) and yohimbine-induced lethality test (YLT) in aggregated mice. Methods: Mice were given JB (10-100 mg/kg, p.o.) daily for 7 days and then subjected to FST, TST, YLT and open fi eld test. The parameters assessed in both FST and TST were the time (s) spent in active movement (struggling time), fi rst occurrence of immobility (s) and the duration of immobility (s). In the YLT, the mortality rate was recorded 24 h after yohimbine (35 mg/kg, i.p.) administration. In the open fi eld test, the number of line crosses and total distance travelled (m) were measured for 10 min in the open fi eld chamber. ■ Proof copy for correction only. All forms of publication, duplication or distribution prohibited under copyright law. ■ therapeutic usefulness in central nervous system disorders [ 4 -7 ] . Although previous studies have confi rmed the anti-anaemic eff ect of JB [ 1 , 2 ] , several other medicinal claims especially in central nervous system disorders are yet to be verifi ed scientifically. This present study which describes the antidepressant property of JB is a part of our ongoing investigations on the psychopharmacological activities of this unique herbal formulation in experimental animals. It is well recognized that a high levels of sustained stress is associated with the natural course of several illnesses especially depression [ 8 ] . Prolonged intense stress produced lowered mood and depletion of monoamines that played crucial role in the regulation of emotion and behavior [ 8 , 9 ] . Thus, a common neurochemical abnormality particularly noradrenergic system/ serotonergic system exist between depressions and prolonged psychosocial stress [ 8 -10 ] . Furthermore, depressed individuals and those under prolonged intense stress exhibit low tolerance to frustration and are more prone to exhaustion [ 8 , 11 ] . The use of JB as an energizer in the state of exhaustion and relieve of stress suggest that it might contain psychopharmacologically active compounds with anti-depressant property. Thus, this present investigation was carried out to evaluate whether Jobelyn ® has anti-depressant-like property in rodent models predictive of endogenous depression in humans.
Results
Materials and Methods
▼
Experimental animals
Male albino Swiss mice (20-22 g ) were obtained from the Central Animal House, University of Ibadan. The animals were housed in plastic cages at room temperature and they had free access to commercial food pellets and water ad libitum. They were acclimatized for at least one week before use for all experiments. The study was carried out in accordance with the ethical guidelines of the University of Ibadan for the care and use of laboratory animals for experimental studies.
Drugs and treatment
Imipramine (IM) hydrochloride (Sigma-Aldrich, St. Louis, USA), yohimbine (Sigma, USA) and Jobelyn ® (Health Forever Products Ltd, Lagos, Nigeria) were used in the study. All drugs were dissolved in distilled water immediately before use and were given orally. The doses of 10, 50 and 100 mg/kg of JB used in the study were selected based on the results obtained from preliminary investigations. All the experimental procedures were started on day 7, 60 min after treatment.
Experimental Procedures
▼
Forced swim test (FST)
The forced swim test is the most widely used test to evaluate depression-like behavior exhibited by mice [ 12 ] . The FST was carried out according to the method of Porsolt et al. [ 13 ] . Mice (6/group) were forced to swim individually in a glass jar (height: 20 cm, diameter: 10 cm) fi lled with water (depth: 15 cm) at a temperature of 25 ± 2 °C for 6 min. The duration of immobility (s) was recorded during the last 4 min of a 6 min observation period. A mouse was judged to be immobile when it remained fl oating in an upright position with the head above the water level. In addition, the struggling time (s) and fi rst occurrence of immobility (s) were also measured. Struggling time was defi ned as the total time spent swimming with active limb motions during the 6 min test. Latency of immobility was defi ned as the duration from the start of the experiment to the fi rst appearance of 4-limb immobility.
Tail suspension test (TST)
The TST was carried out according to the method previously described [ 14 -16 ] . Mice (6/group) were individually suspended by the tail to a cord of about 50 cm in length stretched between 2 metal retort-stands at a height of 70 cm. After the initial 2 min period of vigorous motor activity, the mice became still and the immobility time (s) was measured with a stopwatch for a period of 4 min. Mice were considered immobile when they hung passively and completely motionless [ 14 ] . In addition, the struggling time (s) and fi rst occurrence of immobility (s) were also measured. Struggling time was defi ned as the total time spent with active limb movements during the 6 min test. Latency of immobility was defi ned as the duration from the start of the experiment to the fi rst appearance of 4-limb immobility.
Yohimbine lethality test
The antidepressant eff ect of JB was further evaluated utilizing the potentiation of yohimbine-induced lethality test in mice, as previously described [ 17 ] . Mice (10/group) received JB, 60 min before i.p. injection of yohimbine (35 mg/kg) and were immediately placed in cages. The numbers of death in each group were recorded 24 h after yohimbine administration.
Eff ect of Jobelyn on spontaneous motor activity (SMA)
The open fi eld test was employed to screen the eff ect of JB on SMA in mice. Mice (6 per group) were given JB (10-100 mg/kg, p.o.), IM (25 mg/kg, p.o.), or vehicle (10 ml/kg, p.o.) 60 min before each animal was placed in the center of an open fi eld chamber (72 cm × 72 cm × 36 cm). The number of line crosses and total distance travelled (m) for 10 min were recorded [ 18 ] .
Statistical analysis
The data were expressed as mean ± S.E.M. The data were analyzed with Graph Pad Prism software version 4.03. Statistical analysis of data was done by One-way ANOVA, followed by Tukey post-hoc test. A level of p < 0.05 was considered as statistically signifi cant.
Results
▼
Eff ects of Jobelyn ® on the performance of mice in the forced swim test 
Jobelyn ® potentiates lethality induced by yohimbine in aggregated mice
The eff ect of JB (10, 50 and 100 mg/kg, p.o.) on yohimbineinduced lethality are depicted in • ▶ Fig. 1 . Post-hoc analysis showed that JB (10-50 mg/kg, p.o.) signifi cantly (p < 0.05) potentiated the lethal eff ect of yohimbine (35 mg/kg, i.p.), which was comparable to that of IM. However, at a dose of 100 mg/kg, JB did not signifi cantly (p > 0.05) potentiate the toxic eff ect of yohimbine in mice ( • ▶ Fig. 1 ). Although, JB (10 mg/kg, 50 mg/kg) signifi cantly potentiated the lethal eff ect of yohimbine, it did not produce any toxic symptoms or death in mice when given alone.
Eff ect of Jobelyn
® on spontaneous motor activity • ▶ Table 3 
Discussion
▼
The results of this study revealed that JB reduced the duration of immobility in the forced swim and tail suspension tests in mice, indicating antidepressant-like eff ect. JB also increase the ability of the animals to copy with the aversive situations, as shown by increase in struggling time and delay in the fi rst occurrence of immobility in the FST and TST. The FST and TST are stress models widely used as valid behavioral paradigms for the evaluation of antidepressant drugs in rodents [ 13 , 14 ] . In both tests, rodents are exposed to an aversive situation from which there is no escape, and will, after periods of agitation, cease attempts to escape and become immobile [ 13 , 14 ] . Thus, the appearance of immobility indicates a state of exhaustion, lowered mood (hopelessness) or despairs and antidepressant drugs are known to decrease the period of immobility in rodents [ 12 , 19 ] . However, the anti-immobility eff ect of JB was not associated with central nervous system stimulation, as it did not signifi cantly increase the SMA in the open-fi eld test. This further suggests that the anti-immobility activity exhibited by JB refl ects a true antidepressant-like eff ect. The YLT was further used to validate the antidepressant-like property of JB. The potentiation of yohimbine-induced lethality in aggregated mice has served as an additional paradigm for the routine screening of compounds with antidepressant activity [ 17 ] . Thus, the fi ndings that JB enhanced the lethal eff ect of yohimbine further suggest that it may have antidepressant-like property. ■ Proof copy for correction only. All forms of publication, duplication or distribution prohibited under copyright law. ■
The pathological basis of depression is closely linked with reduced brain levels of monoamines especially norepinephrine and serotonin [ 8 , 9 ] . Although the factors that trigger the depletion of these brain transmitters are not yet clearly established, prolonged intense stress appears to play a predominant role [ 8 , 9 ] . Both preclinical and clinical studies have confi rmed that stress may precipitate depressive illness, as a consequence of the depletion of brain monoamines [ 19 -21 ] . Thus, the most common models predictive of antidepressant activity are performed under intense stressful conditions in rodents [ 12 ] . In addition, antidepressant drugs are known to reduce the duration of immobility through facilitation of both serotonergic and noradrenergic neurotransmissions in these animal models [ 23 -25 ] . Although further studies are necessary before drawing any conclusions on how JB exerts its antidepressant-like action, the data obtained from this present investigation suggests that it possesses phytochemicals that might be interacting with serotonergic and noradrenergic pathways. This suggestion is in accordance with the results obtained from the YLT, as yohimbine is known to interfere with both noradrenaline and serotonin functions [ 26 , 27 ] . Specifi cally, yohimbine induces lethality in grouped mice through the release of catecholamines from the brain and adrenal glands as consequence of antagonism of presynaptic α 2 -adrenergic receptors [ 28 , 29 ] . In addition, antagonism of presynaptic α 2 -adrenergic receptors promotes the release of serotonin, which further contributes to the overall toxicity caused by yohimbine [ 28 , 30 ] . Thus, the major event involved in yohimbine toxicity is an overall increase in serotonergic and noradrenergic neurotransmissions [ 17 ] . Compounds with antidepressant property are known to potentiate the lethal eff ect of yohimbine by enabling the amines to reach the receptors in greater amounts, either by inhibiting their reuptake or by reducing their inactivation [ 17 , 28 , 30 ] . Although the mode of interaction of JB with yohimbine in aggregated mice is yet to be established, previous studies had shown that naringenin, a phenolic compound presence in JB inhibited monoamine oxidase (MAO), an enzyme responsible for the inactivation of monoamines [ 5 , 6 ] . Thus, it is suggestive that the presence of naringenin in JB might be contributing to the overall toxicity of yohimbine in aggregated mice through the elevation of noradrenaline and serotonin levels. Furthermore, studies had also established the antidepressant activity of naringenin, as a consequence of MAO inhibition [ 5 , 6 ] . Therefore, it is likely that the presence of naringenin in JB might be playing a signifi cant role in its antidepressant-like property observed in this study. Psychomotor stimulants which are clinically ineff ective as antidepressants are known to show antidepressant-like eff ects in the FST and TST [ 18 ] . Thus, to discount the possibility of false positives, JB was evaluated for its eff ects on SMA in the open fi eld test. JB did not increase SMA in mice, which suggest that the anti-immobility eff ect, refl ect a true antidepressant-like action, as antidepressant drugs are known to reduce immobility period at doses that do not cause a signifi cant increase in locomotor activity of rodents in the open fi eld tests [ 25 ] .
Conclusion
▼
The present study reveals that JB has antidepressant-like activity and may play a role in the elevation of mood in depressed patients. Furthermore, the ability of JB to delay the onset of immobility and to prolong the struggling time may contribute to its usefulness as an energizer in general body weakness or exhaustion.
